Monoclonal antibodies to meningococcal factor H binding protein with overlapping epitopes and discordant functional activity

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Giuntini, Serena ^a   Beernink, Peter T ^a   Reason, Donald C ^a   Granoff, Dan M ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ANTIBODY; ARGININE; ASPARTIC ACID; BINDING PROTEIN; COMPLEMENT FACTOR H; EPITOPE; IMMUNOGLOBULIN G; LYSINE; MENINGOCOCCAL FACTOR H BINDING PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY FHBP; MONOCLONAL ANTIBODY JAR1; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; FACTOR H BINDING PROTEIN, NEISSERIA MENINGITIDIS; FACTOR H-BINDING PROTEIN, NEISSERIA MENINGITIDIS; MENINGOCOCCUS VACCINE; RECOMBINANT PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CHIMERA; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG TARGETING; NEISSERIA MENINGITIDIS; NONHUMAN; NUCLEOTIDE SEQUENCE; SITE DIRECTED MUTAGENESIS; ANIMAL; ANTIBODY SPECIFICITY; BACTERIOLYSIS; BAGG ALBINO MOUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; MOUSE; PROTEIN BINDING; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BACTERIOLYSIS; COMPLEMENT FACTOR H; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPITOPES; HUMANS; MENINGOCOCCAL VACCINES; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; NEISSERIA MENINGITIDIS, SEROGROUP B; PROTEIN BINDING; RECOMBINANT PROTEINS;

EID: 84858844319     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034272     Document Type: Article

References (52)

1. Granoff DM, (2010) Review of meningococcal group B vaccines. Clin Infect Dis 50 (Suppl 2): S54-65.
2. Finne J, Bitter-Suermann D, Goridis C, Finne U, (1987) An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 138: 4402-4407.
3. Finne J, Leinonen M, Makela PH, (1983) Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 2: 355-357.
4. Jennings HJ, Roy R, Gamian A, (1986) Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J Immunol 137: 1708-1713.
5. Gottfredsson M, Reynisson IK, Ingvarsson RF, Kristjansdottir H, Nardini MV, et al. (2011) Comparative long-term adverse effects elicited by invasive group B and C meningococcal infections. Clin Infect Dis 53: e117-124.
6. Robbins JB, Schneerson R, Xie G, Ake-Hanson L, Miller MA, (2011) Capsular polysaccharide vaccine for Group B Neisseria meningitidis, Escherichia coli K1, and Pasteurella haemolytica A2. Proc Natl Acad Sci U S A 108: 17871-17875.
7. Sadarangani M, Pollard AJ, (2010) Serogroup B meningococcal vaccines-an unfinished story. Lancet Infect Dis 10: 112-124.
8. Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, et al. (2006) A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 103: 10834-10839.
9. Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, et al. (2004) Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 72: 2088-2100.
10. Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, et al. (2006) The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 177: 501-510.
11. Schneider MC, Exley RM, Ram S, Sim RB, Tang CM, (2007) Interactions between Neisseria meningitidis and the complement system. Trends Microbiol 15: 233-240.
12. Schneider MC, Exley RM, Chan H, Feavers I, Kang YH, et al. (2006) Functional significance of factor H binding to Neisseria meningitidis. J Immunol 176: 7566-7575.
13. Granoff DM, Welsch JA, Ram S, (2009) Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun 77: 764-769.
14. Vu DM, Shaughnessy J, Lewis LA, Ram S, Rice PA, et al. (2011) Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidis. Infect Immun.
15. Snape MD, Dawson T, Oster P, Evans A, John TM, et al. (2010) Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 29: e71-79.
16. Findlow J, Borrow R, Snape MD, Dawson T, Holland A, et al. (2010) Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 51: 1127-1137.
17. Jiang H-Q, Harris SL, Tan C, Scott A, Alexander K, et al. Prediction of broad vaccine coverage for a bivalent rLP2086 based vaccine which elicits serum bactericidal activity against a diverse collection of serogroup B Meningococci. In: van Alphen L, van Ley P, van den Dobbelsteen G, editors. 2008 September 7-12, 2008; Rotterdam, The Netherlands.
18. Keiser PB, Biggs-Cicatelli S, Moran EE, Schmiel DH, Pinto VB, et al. (2011) A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 29: 1413-1420.
19. Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, et al. (2003) Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 197: 789-799.
20. Beernink PT, Granoff DM, (2009) The modular architecture of meningococcal factor H-binding protein. Microbiology 155: 2873-2883.
21. Pajon R, Beernink PT, Harrison LH, Granoff DM, (2010) Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 28: 2122-2129.
22. Welsch JA, Rossi R, Comanducci M, Granoff DM, (2004) Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J Immunol 172: 5606-5615.
23. Welsch JA, Ram S, Koeberling O, Granoff DM, (2008) Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis 197: 1053-1061.
24. Pajon R, Fergus AM, Koeberling O, Caugant DA, Granoff DM, (2011) Meningococcal factor H binding proteins in epidemic strains from Africa: Implications for vaccine development. PLoS Negl Trop Dis 5: e1302.
25. Giuntini S, Reason DC, Granoff DM, (2012) Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein. Infect Immun 80: 187-194.
26. Beernink PT, Granoff DM, (2008) Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines. Infect Immun 76: 2568-2575.
27. Giuntini S, Reason DC, Granoff DM, (2011) Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect Immun 79: 3751-3759.
28. Giuliani MM, Santini L, Brunelli B, Biolchi A, Arico B, et al. (2005) The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect Immun 73: 1151-1160.
29. Scarselli M, Cantini F, Santini L, Veggi D, Dragonetti S, et al. (2009) Epitope mapping of a bactericidal monoclonal antibody against the factor H binding protein of Neisseria meningitidis. J Mol Biol 386: 97-108.
30. Giuntini S, Reason DC, Granoff DM, (2011) Complement-mediated bactericidal activity of anti-fHbp monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect Immun.
31. Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, et al. (2009) Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 200: 379-389.
32. Beernink PT, Welsch JA, Bar-Lev M, Koeberling O, Comanducci M, et al. (2008) Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate, factor H-binding protein. Infect Immun 76: 4232-4240.
33. Huson DH, Bryant D, (2006) Application of phylogenetic networks in evolutionary studies. Mol Biol Evol 23: 254-267.
34. Lewis LA, Ngampasutadol J, Wallace R, Reid JE, Vogel U, et al. (2010) The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog 6: e1001027.
35. Michaelsen TE, Kolberg J, Aase A, Herstad TK, Hoiby EA, (2004) The four mouse IgG isotypes differ extensively in bactericidal and opsonophagocytic activity when reacting with the P1.16 epitope on the outer membrane PorA protein of Neisseria meningitidis. Scand J Immunol 59: 34-39.
36. Mascioni A, Bentley BE, Camarda R, Dilts DA, Fink P, et al. (2009) Structural basis for the immunogenic properties of the meningococcal vaccine candidate LP2086. J Biol Chem 284: 8738-8746.
37. Cantini F, Savino S, Scarselli M, Masignani V, Pizza M, et al. (2006) Solution structure of the immunodominant domain of protective antigen GNA1870 of Neisseria meningitidis. J Biol Chem 281: 7220-7227.
38. Schneider MC, Prosser BE, Caesar JJ, Kugelberg E, Li S, et al. (2009) Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 458: 890-893.
39. Beernink PT, Lopasso C, Angiolillo A, Felici F, Granoff D, (2009) A region of the N-terminal domain of meningococcal factor H-binding protein that elicits bactericidal antibody across antigenic variant groups. Mol Immunol 46: 1647-1653.
40. Beernink PT, Caugant DA, Welsch JA, Koeberling O, Granoff DM, (2009) Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. J Infect Dis 199: 1360-1368.
41. Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, et al. (2010) Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 28: 6086-6093.
42. Scarselli M, Arico B, Brunelli B, Savino S, Di Marcello F, et al. (2011) Rational design of a meningococcal antigen inducing broad protective immunity. Sci Transl Med 3: 91ra62.
43. Beernink PT, Shaughnessy J, Braga EM, Liu Q, Rice PA, et al. (2011) A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol 186: 3606-3614.
44. Azmi FH, Lucas AH, Raff HV, Granoff DM, (1994) Variable region sequences and idiotypic expression of a protective human immunoglobulin M antibody to capsular polysaccharides of Neisseria meningitidis group B and Escherichia coli K1. Infect Immun 62: 1776-1786.
45. Boder ET, Wittrup KD, (1997) Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15: 553-557.
46. Chao G, Cochran JR, Wittrup KD, (2004) Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display. J Mol Biol 342: 539-550.
47. Gasteiger J, (2006) Chemoinformatics: a new field with a long tradition. Anal Bioanal Chem 384: 57-64.
48. Dunphy KY, Beernink PT, Brogioni B, Granoff DM, (2011) Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood. Infect Immun 79: 353-359.
49. Beernink PT, Leipus A, Granoff DM, (2006) Rapid genetic grouping of factor H-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate. Clin Vaccine Immunol 13: 758-763.
50. Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, et al. (1998) Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 95: 3140-3145.
51. Brehony C, Wilson DJ, Maiden MC, (2009) Variation of the factor H-binding protein of Neisseria meningitidis. Microbiology 155: 4155-4169.
52. Plested JS, Granoff DM, (2008) Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B. Clin Vaccine Immunol 15: 799-804.